SCHEMBL7230623

SCHEMBL7230623

COc1ccc2[nH]c(C)c(C3=C(O)C(=O)C(c4c(C(=O)O)[nH]c5ccc(Cl)cc45)=C(O)C3=O)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 4/20 0.50
MAPT P10636 3/20 0.46
GAA P10253 8/20 0.44
MEN1 O00255 6/20 0.44
KMT2A Q03164 6/20 0.44
CDK5 Q00535 2/20 0.44
CDK5R1 Q15078 2/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
GFER P55789 1/20 0.44
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 4/20 0.44
HSD17B10 Q99714 2/20 0.44
AKR1C2 P52895 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
POLB P06746 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7234412 0.85 ALDH1A1 (0.51) MAPTGAAMEN1KMT2ACDK5
SCHEMBL7230887 0.82 LMNA (0.50) MAP2MAPTGAAMEN1KMT2A
SCHEMBL6096397 0.76 ALDH1A1 (0.46) MAPTGAAMEN1KMT2ACDK5
SCHEMBL6252220 0.76 KDM4E (0.55) MAP2MAPTGAAMEN1KMT2A
SCHEMBL6094945 0.74 MAP3K14 (0.44) MAP2MAPTGAAGSK3AGSK3B
SCHEMBL2730951 0.71 KDM4E (0.61) MAPTGAAMEN1KMT2ACDK5
SCHEMBL7234849 0.71 MAP2 (0.50) MAP2MAPTKDM4EALDH1A1HPGD
SCHEMBL2396662 0.71 KDM4E (0.72) MAPTGAAMEN1KMT2ACDK5
SCHEMBL30779659 0.70 KDM4E (0.63) MAPTGAAMEN1KMT2ACDK5
SCHEMBL6098106 0.70 ALDH1A1 (0.45) MAPTMEN1KMT2ACDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020156116-A1 Bis-indolyquinone compounds TANG PENG CHO (US) 2002-10-24 US claimed
EP-1218342-A2 MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF Sugen, Inc. (US) 2002-07-03 EP claimed
US-6376529-B1 INSULIN DISEASES; ANTIDIABETIC AGENTS SUGEN, INC. 2002-04-23 US claimed
WO-2001021589-A2 MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF SUGEN, INC. (US) 2001-03-29 WO claimed
US-6660763-B2 Antiproliferative agents for disorders with GRB-2 adaptor protein function; treating diabetes, insulin resistance, insulin deficiency and insulin allergy SUGEN, INC. 2003-12-09 US disclosed
US-20020156116-A1 Bis-indolyquinone compounds TANG PENG CHO (US) 2002-10-24 US disclosed
EP-1218342-A2 MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF Sugen, Inc. (US) 2002-07-03 EP disclosed
US-6376529-B1 INSULIN DISEASES; ANTIDIABETIC AGENTS SUGEN, INC. 2002-04-23 US disclosed
WO-2001021589-A2 MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF SUGEN, INC. (US) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156116-A1 Bis-indolyquinone compounds IRS1, GRK2, GID4 MAP2 1159/4885MAPT 3236/4885GAA 3027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.